Lanean...
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
The discovery of BCR/ABL as a driver oncogene in chronic myeloid leukemia (CML) resulted in the development of Imatinib, which, in fact, demonstrated the potential of targeting the kinase in cancers by effectively treating the CML patients. This observation revolutionized drug development to target...
Gorde:
| Argitaratua izan da: | J Vis Exp |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MyJove Corporation
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4362691/ https://ncbi.nlm.nih.gov/pubmed/25549138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3791/51984 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|